News

Home | News

SingaporeGroundbreakingGroupPhoto WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers

WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers

Photo caption (from left to right): Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board; Dr. Minzhang Chen, Co-CEO, WuXi AppTec; Mr. Heng Swee Keat, Deputy Prime Minister; Dr. Ge Li,…

1712611282014 A Successful PAI for a new Peptide Drug from Japan PMDA

A Successful PAI for a new Peptide Drug from Japan PMDA

Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide drug. The 3-day inspection, without any major…

CDMO2024 2024 CDMO Leadership Awards

2024 CDMO Leadership Awards

Exciting moment! We’ve been honored with the 2024 CDMO Leadership Awards in all six core categories: Capabilities, Compatibility, Expertise, Quality, Reliability, and Service, again! Dr. Jinling Chen, our Senior Vice President and…

WuXi_STA_Taixing_site

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand Shanghai, China – January 8, 2024 — WuXi AppTec, a global company that provides a broad…

WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site

WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site

Shanghai, China, July 17, 2023 -- WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), today launched its first high potency (HP), fully automated sterile injectable manufacturing line at the…

WuXi STA Forms Strategic Partnership with Ark Biopharmaceutical for the Commercial Supply of Ziresovir WuXi STA Forms Strategic Partnership with Ark Biopharmaceutical for the Commercial Supply of Ziresovir

WuXi STA Forms Strategic Partnership with Ark Biopharmaceutical for the Commercial Supply of Ziresovir

SHANGHAI, CHINA, May 23, 2023 - WuXi STA, a subsidiary of WuXi AppTec, and Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a strategic partnership for the commercial supply of ziresovir, a novel…

Scroll to Top
Please enable JavaScript in your browser to complete this form.
Checkboxes